Significance of Dynamic Changes of VCA-IgA Levels in Pre- and Post-treatment Plasma of Patients with Nasopharyngeal Carcinoma: Development of a Clinically-Oriented Model

[1]  R. Haddad,et al.  Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review. , 2022, Cancer treatment reviews.

[2]  Xiaoping Lin,et al.  Radioresistant Nasopharyngeal Carcinoma Cells Exhibited Decreased Cisplatin Sensitivity by Inducing SLC1A6 Expression , 2021, Frontiers in Pharmacology.

[3]  T. Du,et al.  MiR-138-1-3p alters the stemness and radiosensitivity of tumor cells by targeting CRIPTO and the JAK2/STAT3 pathway in nasopharyngeal carcinoma , 2021, Annals of translational medicine.

[4]  M. Tan,et al.  Clinical utility of Epstein‐Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma , 2020, Cancer communications.

[5]  Huijuan Zhang,et al.  Inhibitory effect of simiao qingwen baidu decoction on epstein-barr virus EA, VCA expression and DNA replication in vitro. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  Lichuan Wu,et al.  Chemotherapy and chemo-resistance in nasopharyngeal carcinoma. , 2020, European journal of medicinal chemistry.

[7]  Xueping Wang,et al.  A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma , 2020, Advances in Therapy.

[8]  Anne W. M. Lee,et al.  Emerging radiotherapy technologies and trends in nasopharyngeal cancer , 2020, Cancer communications.

[9]  Wei-guo Huang,et al.  Circular RNAs in Nasopharyngeal Carcinoma. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[10]  L. Ke,et al.  MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  He Xiao,et al.  Serum miRNAs, a potential prognosis marker of loco-regionally advanced nasopharyngeal carcinoma patients treated with CCRT , 2019, BMC Cancer.

[12]  Wei Jiang,et al.  Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis , 2019, Journal of Immunotherapy for Cancer.

[13]  Xun Jin Ng,et al.  Systematic comparison of plasma EBV DNA, anti‐EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma , 2019, International journal of cancer.

[14]  Kwok Wai Lo,et al.  Epstein–Barr virus infection and nasopharyngeal carcinoma , 2017, Philosophical Transactions of the Royal Society B: Biological Sciences.

[15]  Ping Li,et al.  Cigarette smoking and the risk of nasopharyngeal carcinoma: a meta-analysis of epidemiological studies , 2017, BMJ Open.

[16]  J. Miao,et al.  PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load , 2017, Scientific Reports.

[17]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[18]  Elena B. Elkin,et al.  Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers , 2008, BMC Medical Informatics Decis. Mak..

[19]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.